硅寶科技(300019.SZ):目前1000噸/年中試線穩定運行,累計實現百噸級銷售
格隆匯4月7日丨 硅寶科技(300019.SZ)於近期投資者關係活動表示,公司硅碳負極業務在2024年實現重大突破,完成從技術研發到規模化銷售的關鍵跨越。目前1000噸/年中試線穩定運行,累計實現百噸級銷售,其中新型硅碳產品取得噸級突破,目前佔公司營業收入比重不高。隨着3000噸/年產能建設推進,公司正重點發力預鎂硅氧和新型硅碳產品,深化與戰略客戶從研發到量產的全程合作,加速硅碳負極在高端電池市場的商業化進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.